Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer

Join the discussion! We bring the expert to you. LIVE. VIRTUAL. FLEXIBLE. Interactive discussion on optimization of RET+ testing in NSCLC and thyroid cancer, and the pathways for enhancing collaboration between pathologists and oncologists to improve patient care.

Your questions answered on precision medicine!

- What are the roles of biomarkers?

- When should biomarker testing occur?

- What do the test results mean?

- How does the mutational burden impact treatment selection?

- When should novel agents be selected?

- How can pathologists help inform treatment decisions?

- How can barriers to collaboration between pathologists and oncologists be overcome?

- How can collaboration between pathologists and oncologists improve patient outcomes?

Clinicians, be ready for the future and stay at the forefront of precision medicine in cancer care.

Each live webinar will address RET alterations in NSCLC and thyroid cancer, testing for RET fusions and RET alterations, and treatment selection for RET+ NSCLC and thyroid cancer. Following didactic presentations, a case study featuring either an NSCLC or thyroid patient will be reviewed and discussed with participants. To view a list of webinar dates and times with corresponding case study focus, click on the link below.